Earlier this week, Star Therapeutics’ von Willebrand disease candidate – VGA039 – was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). While it is the most common inherited bleeding disorder and affects about 1% of the population, you don’t hear about von Willebrand disease every day. With Star Therapeutics’ candidate getting some recognition from the FDA...